Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA

Alien R. Doran, David R. Rubinow, Owen M. Wolkowitz, Alec Roy, Alan Breier, David Pickar

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

CSF somatostatin and homovanillic acid (HVA) were measured in 14 schizophrenic patients while they were drug-free and during chronic fluphenazine treatment. CSF somatostatin was significantly reduced and CSF HVA was significantly elevated (p <0.002) during fluphenazine treatment. There was a trend toward correlation between CSF somatostatin and CSF HVA in the 14 schizophrenic patients when drug-free (r = 0.49, p <0.07) and fluphenazine-treated (r = 0.47, p <0.08). When examined in a larger group (n = 46) of drug-free schizophrenics, this relationship was highly significant (r = 0.59, p <0.001). These clinical data are consistent with preclinical evidence indicating a functional interaction between CMS somatostatin and dopamine systems.

Original languageEnglish (US)
Pages (from-to)431-439
Number of pages9
JournalBiological Psychiatry
Volume25
Issue number4
DOIs
StatePublished - Feb 15 1989
Externally publishedYes

Fingerprint

Fluphenazine
Homovanillic Acid
Somatostatin
Schizophrenia
Pharmaceutical Preparations
Therapeutics
Dopamine

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia : Correlations with CSF HVA. / Doran, Alien R.; Rubinow, David R.; Wolkowitz, Owen M.; Roy, Alec; Breier, Alan; Pickar, David.

In: Biological Psychiatry, Vol. 25, No. 4, 15.02.1989, p. 431-439.

Research output: Contribution to journalArticle

Doran, Alien R. ; Rubinow, David R. ; Wolkowitz, Owen M. ; Roy, Alec ; Breier, Alan ; Pickar, David. / Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia : Correlations with CSF HVA. In: Biological Psychiatry. 1989 ; Vol. 25, No. 4. pp. 431-439.
@article{621d22865503480bbc52c07b4d192c2d,
title = "Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA",
abstract = "CSF somatostatin and homovanillic acid (HVA) were measured in 14 schizophrenic patients while they were drug-free and during chronic fluphenazine treatment. CSF somatostatin was significantly reduced and CSF HVA was significantly elevated (p <0.002) during fluphenazine treatment. There was a trend toward correlation between CSF somatostatin and CSF HVA in the 14 schizophrenic patients when drug-free (r = 0.49, p <0.07) and fluphenazine-treated (r = 0.47, p <0.08). When examined in a larger group (n = 46) of drug-free schizophrenics, this relationship was highly significant (r = 0.59, p <0.001). These clinical data are consistent with preclinical evidence indicating a functional interaction between CMS somatostatin and dopamine systems.",
author = "Doran, {Alien R.} and Rubinow, {David R.} and Wolkowitz, {Owen M.} and Alec Roy and Alan Breier and David Pickar",
year = "1989",
month = "2",
day = "15",
doi = "10.1016/0006-3223(89)90196-0",
language = "English (US)",
volume = "25",
pages = "431--439",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia

T2 - Correlations with CSF HVA

AU - Doran, Alien R.

AU - Rubinow, David R.

AU - Wolkowitz, Owen M.

AU - Roy, Alec

AU - Breier, Alan

AU - Pickar, David

PY - 1989/2/15

Y1 - 1989/2/15

N2 - CSF somatostatin and homovanillic acid (HVA) were measured in 14 schizophrenic patients while they were drug-free and during chronic fluphenazine treatment. CSF somatostatin was significantly reduced and CSF HVA was significantly elevated (p <0.002) during fluphenazine treatment. There was a trend toward correlation between CSF somatostatin and CSF HVA in the 14 schizophrenic patients when drug-free (r = 0.49, p <0.07) and fluphenazine-treated (r = 0.47, p <0.08). When examined in a larger group (n = 46) of drug-free schizophrenics, this relationship was highly significant (r = 0.59, p <0.001). These clinical data are consistent with preclinical evidence indicating a functional interaction between CMS somatostatin and dopamine systems.

AB - CSF somatostatin and homovanillic acid (HVA) were measured in 14 schizophrenic patients while they were drug-free and during chronic fluphenazine treatment. CSF somatostatin was significantly reduced and CSF HVA was significantly elevated (p <0.002) during fluphenazine treatment. There was a trend toward correlation between CSF somatostatin and CSF HVA in the 14 schizophrenic patients when drug-free (r = 0.49, p <0.07) and fluphenazine-treated (r = 0.47, p <0.08). When examined in a larger group (n = 46) of drug-free schizophrenics, this relationship was highly significant (r = 0.59, p <0.001). These clinical data are consistent with preclinical evidence indicating a functional interaction between CMS somatostatin and dopamine systems.

UR - http://www.scopus.com/inward/record.url?scp=0024518302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024518302&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(89)90196-0

DO - 10.1016/0006-3223(89)90196-0

M3 - Article

C2 - 2564787

AN - SCOPUS:0024518302

VL - 25

SP - 431

EP - 439

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 4

ER -